Novo Nordisk and Octagon Therapeutics Enter Inflammatory Disease Research Collaboration

Article

The collaboration will use Octagon’s functional target discovery approach and novel chemistry strategy in disease areas in which Novo Nordisk has specific expertise.

Octagon Therapeutics, a preclinical-stage biotechnology company, announced a partnership with Novo Nordisk on Sept. 20, 2022. The research collaboration will use Octagon’s functional target discovery approach and novel chemistry strategy in disease areas in which Novo Nordisk has specific expertise.

The program selectively targets a population of pathologically activated B cells that contribute to autoimmune diseases like systemic lupus and vasculitis. According to a company press release, this approach can be applied in other disease areas to target disease-driving processes while retaining healthy immune functioning. A recent pilot project, initiated through Novo Nordisk’s Co-creation Greenhouse Accelerator program, demonstrated proof-of-concept in identifying atypical characteristics of other immune cells during disease; this ultimately led to the discovery of new therapeutic targets.

"Octagon has a unique platform technology to look into functional biology in a novel way.It makes use of clinical samples and primary immune cells to identify new drug targets,” said Uli Stilz, vice-president, Bio Innovation Hub, Novo Nordisk, in the press release. “Combined with our disease understanding in the cardiometabolic space and Octagon´s approach in targeting specific lymphocyte populations that drive disease progression, it will be exciting to see what therapeutic discoveries the collaboration can lead to."

"Novo Nordisk has a strong expertise in diabetes and related cardiometabolic conditions like [nonalcoholic fatty liver disease] and kidney disease." said Isaac Stoner, CEO, Octagon Therapeutics, in the press release."This collaboration will enable Octagon to expand our technology into these disease areas and to further leverage the impressive clinical sample collection that Novo Nordisk has available."

Source: Octagon Therapeutics

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content